CARMAT publishes 2024 half-year results and provides update on outlook

Regulatory News:

CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, with the aim of providing a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “KARMAT”), today announces its results for the first half year ending June 30, 2024²and provides an update on progress and prospects.

Stéphane Piat, CEO of CARMAT, comments: “The outcome of the first half of 2024 is very positive. With a turnover of €3.3 million, we have exceeded our entire annual turnover of 2023 in just 6 months. Achieving 20 Aeson implants in the first half of the year is a very encouraging indicator for such an innovative device, which is still in the launch phase. In the second quarter of 2024, we will have performed twice as many implants as in the first quarter.